… problems in the treatment of patients with COVID-19. This study provides an overview of
IVIG treatment in patients with COVID-19 and the probable effects of IVIG on virus infections. …

… In the context of COVID-19, the actual role of IVIG … IVIG for the treatment of COVID-19 in 12
patients (9 male) with an average age of 50 years (range 23–74 years) and severe COVID-19. …

… immunoglobulin (IVIG) is commonly used to treat severe COVID-19, although the clinical
outcome of such treatment … the effectiveness of IVIG treatment in severe COVID-19 patients. …

… of this drug in the treatment of various diseases, the present study aims to investigate the
effects of IVIG administration on the outcome of COVID-19 patients with severe symptoms …

… not support use of IVIg in hospitalised adult COVID-19 patients. … immunoglobulin treatment
(IVIg) has any impact on mortality or hospitalisation duration in hospitalised adult COVID-19 …

… against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment
… Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy …

… IVIg was a safe and effective treatment for COVID-19-related encephalopathy in our case
series. Clinical efficacy may be driven by the anti-inflammatory action of IVIg, associated with …

… during the COVID-19 pandemic to assess whether convalescent plasma or intravenous
immunoglobulin (IVIG) transfusion is effective and safe in the treatment of COVID-19 patients. …

… therapy, but the treatment of COVID-19 by IVIG is controversial. … of IVIG in the treatment of
children with severe COVID-19. … on the use of IVIG in patients with COVID-19, severe acute …

… of IVIG (Intravenous Immunoglobulin) therapy for COVID-19 remains controversial. We
performed a meta-analysis to investigate the efficacy of IVIG treatment in patients with COVID-19. …